28 May, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
13 May, 2025 in Investor Relations Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
06 May, 2025 in Investor Relations Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
05 May, 2025 in Investor Relations Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
01 May, 2025 in Investor Relations Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
